Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) that leads to progressive and irreversible loss of central vision1 . It affects millions worldwide, particularly adults over 60, and can severely impact daily activities such as reading, driving, and recognizing faces2 . While GA primarily results from the dry form of AMD, recent medical advances have introduced new treatment options that can slow its progression3 .
Age-Related Macular Degeneration Types
Age-related macular degeneration is a progressive retinal disease that mainly affects the macula, the central part of the retina responsible for detailed vision and color perception3 . AMD is classified into two main types: dry (atrophic) and wet (neovascular), both of which can lead to geographic atrophy4 .
Dry AMD
Dry AMD is the more common and slowly progressing form of the disease5 . It is characterized by the accumulation of drusen—yellow deposits beneath the retina—and atrophy of the retinal pigment epithelium (RPE), which supports the photoreceptors4 . Dry AMD progresses through early, intermediate, and advanced stages, with geographic atrophy representing the late stage6 . Early stages are often asymptomatic, but late dry AMD causes central vision loss manifested as scotomas or dark spots7 . Geographic atrophy arises primarily from dry AMD and increases the risk of progression to wet AMD8 .
Wet AMD
Wet AMD is an advanced form characterized by rapid progression due to abnormal blood vessel growth beneath the retina, known as choroidal neovascularization4 . This abnormal vessel growth leads to leakage and bleeding, causing sudden and severe vision loss4 . Vascular endothelial growth factor (VEGF) is a key mediator stimulating this abnormal blood vessel growth5 . Although wet AMD accounts for only 10–20% of AMD cases, it causes the majority of severe vision loss4 . Urgent intervention is required to manage wet AMD due to its rapid progression6 .
Geographic Atrophy Symptoms and Signs
Geographic atrophy often begins in one eye but commonly affects both eyes over time7 . It causes progressive, irreversible central vision loss as the atrophic lesions enlarge and involve the fovea, the center of the macula responsible for sharp vision4 9. Early GA may be asymptomatic, with vision changes becoming noticeable only as the disease advances10 .
Key symptoms and signs of GA include:
- Progressive central vision impairment, making reading, recognizing faces, and seeing in dim light difficult10
- Central scotomas or dark spots causing missing letters or words during reading7
- Need for increased lighting to perform visual tasks10
- Blurred central vision as lesions enlarge4
- Colors appearing faded or less vivid7
- Peripheral vision typically remains intact, preserving side vision4
These symptoms significantly affect quality of life and independence11 .
Geographic atrophy affects central vision, impacting the ability to drive, read, and recognize faces. Peripheral vision usually remains, allowing some visual function to be preserved12 2.
Causes and Risk Factors of Geographic Atrophy
Geographic atrophy results from the progressive loss of photoreceptors and retinal pigment epithelium cells in the macula4 . The exact triggers of AMD and GA remain unclear but involve complex genetic and environmental factors13 . Drusen accumulation disrupts RPE function and contributes to dry AMD and GA development8 . GA lesions typically start in the perifoveal region and expand to involve the fovea, leading to central vision loss9 .
Risk Factors
Several factors increase the risk of developing GA:
- Age over 60, with prevalence rising significantly in older adults14 2
- Genetic predisposition and family history of macular degeneration9 2
- Smoking or past tobacco use, which increases AMD and GA risk13 2
- Cardiovascular health issues such as hypertension and high cholesterol13 2
- Postmenopausal status without hormone therapy13
- Poor diet lacking fruits, vegetables, and omega-3 fatty acids13 2
- Excessive sun exposure without eye protection2
- Conditions like obesity and diabetes2
Unilateral GA also increases the risk of developing GA in the fellow eye7 .
Diagnosing Geographic Atrophy
Diagnosis of GA requires a comprehensive eye examination and multimodal imaging techniques to assess the extent of retinal damage15 . The macula is examined carefully since it is responsible for detailed central vision7 . GA lesions often begin in the perifoveal area and expand to the fovea, causing central vision loss9 .
Diagnostic tools and procedures include:
- Visual acuity testing to evaluate central vision loss16
- Dilated fundus examination to visualize the macula and GA lesions15
- Amsler grid testing to detect central visual distortions or scotomas16
- Microperimetry to assess retinal sensitivity and functional loss1
- Fundus photography to document lesion size and progression16
- Optical coherence tomography (OCT) to provide cross-sectional images of retinal layers and detect atrophy17
- Fluorescein angiography, mainly used to detect abnormal blood vessels in wet AMD but less common for GA diagnosis4
Regular monitoring is essential, especially since GA progression can be relentless and may lead to further vision impairment15 .
Geographic Atrophy Treatment Options
Until recently, no FDA-approved treatments existed for GA, and vision loss was considered irreversible due to permanent retinal cell death4 . However, new therapies targeting the complement system have been approved, offering hope to slow disease progression18 .
Izervay Injection
Izervay (avacincaptad pegol) is a complement C5 inhibitor approved by the FDA in 2023 for GA treatment3 . It is administered as monthly intravitreal injections directly into the eye3 . Clinical trials demonstrated a 27–30% reduction in GA lesion growth with this treatment19 .
Syfovre Injection
Syfovre (pegcetacoplan) is a complement C3 inhibitor also approved in early 2023 for GA18 . It is given intravitreally every 1 to 2 months20 . Syfovre similarly slows the progression of GA by targeting the complement cascade involved in retinal cell damage18 .
Anti-VEGF Injection
Anti-VEGF therapies are effective in treating wet AMD by inhibiting abnormal blood vessel growth4 . These injections are administered under local anesthesia using fine needles and require repeated dosing to maintain disease control4 5.
Photodynamic Therapy
Photodynamic therapy with verteporfin may be combined with anti-VEGF treatment for certain wet AMD cases to improve outcomes4 .
Vitamin Supplements
AREDS2 supplements, containing high-dose vitamins and minerals, may slow the progression of intermediate dry AMD to late-stage disease but have limited effect once GA develops21 .
| Treatment Option | Target Mechanism | Administration Frequency | Effect on GA Progression |
|---|---|---|---|
| Izervay (avacincaptad pegol) | Complement C5 inhibition | Monthly intravitreal injection | ~27–30% reduction in lesion growth3 19 |
| Syfovre (pegcetacoplan) | Complement C3 inhibition | Every 1–2 months intravitreal injection | Slows GA progression18 20 |
| Anti-VEGF Injections | VEGF inhibition | Repeated intravitreal injections | Controls wet AMD, not GA4 5 |
| Photodynamic Therapy | Vascular occlusion | Combined with anti-VEGF as needed | Used for wet AMD4 |
| AREDS2 Supplements | Antioxidant support | Daily oral supplements | May slow dry AMD progression21 |
| Sources: 34518192021 | |||
“It seems like every year or two we get either a new therapy or a new approach or thinking that improves our patients' quality of life, and that's very exciting.”
— Carl Regillo22
Preventing Geographic Atrophy Progression
While GA vision loss is irreversible, certain lifestyle modifications and management strategies can reduce the risk and slow progression13 23. Prevention focuses on minimizing risk factors and preserving remaining vision.
Key prevention strategies include:
- Smoking cessation to reduce AMD and GA risk13 2
- Maintaining cardiovascular health by managing hypertension and cholesterol13
- Eating a diet rich in leafy greens, fruits, vegetables, and omega-3 fatty acids13 2
- Wearing UV-blocking sunglasses to protect retinal health13
- Regular ophthalmic monitoring to detect early changes and intervene promptly15
Regular use of the Amsler grid at home helps patients detect early visual changes and report them to their eye care provider16 .
Conditions Related to Geographic Atrophy
GA is a late-stage manifestation of dry AMD and is associated with several related conditions and complications4 . It significantly impacts patients' quality of life and mental health11 .
Related conditions and complications include:
- Progression to neovascular (wet) AMD, which requires urgent treatment8
- Legal blindness due to irreversible central vision loss7
- Depression and anxiety, with vision impairment doubling the risk of anxiety disorders24 4
- Charles Bonnet syndrome, causing visual hallucinations in some patients21
- Increased dependence and reduced independence in daily activities11
Regular follow-up and supportive care are essential to manage these complications15 .
Managing Life with Geographic Atrophy
Living with GA involves adapting to progressive vision loss and maintaining quality of life through rehabilitation and support11 . Patients benefit from vision rehabilitation and adaptive strategies to cope with central vision impairment11 .
Depression is common among patients with geographic atrophy due to vision loss and reduced independence, highlighting the importance of psychological support and peer groups11 24.
Helpful management approaches include:
- Use of magnifiers and large-print materials to aid reading11
- Enhanced lighting conditions to improve visual tasks11
- Digital accessibility tools and voice recognition software to support communication11
- Psychological support and peer support groups to address emotional challenges24 11
- Regular follow-up every 6 months to monitor disease progression and adjust care15
Vision rehabilitation can significantly improve independence and daily functioning despite vision loss11 .
